ArticleCirculation. Heart failure2026
Multimodal Framework of Left Heart-Pulmonary Vascular Remodeling Underlying Right Ventricular Failure in PH-HFpEF.
Article in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundRight ventricular (RV) dysfunction in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) leads to adverse outcomes, yet the mechanisms underlying RV failure remain incompletely defined. We aimed to develop a multimodal framework integrating vascular mechanics and myocardial transcriptomics for a mechanistic understanding of RV dysfunction in PH-HFpEF.
methodsIn a 2-step study, a predominantly retrospective PH-HFpEF cohort (n=48) underwent comprehensive assessment with clinical evaluation, echocardiography, cardiac magnetic resonance imaging (MRI), and invasive cardiopulmonary exercise testing. Based on cardiac MRI-derived RV ejection fraction <45%, the PH-HFpEF cohort was stratified into a normal RV function group (n=29) and an RV dysfunction group (n=19). A prospective subset underwent pulmonary vascular mechanics (impedance and wave intensity analysis, n=17), 4-dimensional flow cardiac MRI (n=15), and endomyocardial biopsy with long-read RNA sequencing (n=10).
resultsPH-HFpEF participants with RV dysfunction had worse 1-year outcomes (mortality or first heart failure hospitalization; hazard ratio, 8.2 [95% CI, 2.5-25.4]) and exhibited multisystem limitations (abnormal cardiac reserve, pulmonary vascular, and ventilatory function). Compared with the normal RV subgroup, the RV dysfunction subgroup had impaired left ventricular longitudinal strain on cardiac MRI. Pulmonary vascular mechanics demonstrated increased proximal pulmonary arterial stiffness (characteristic impedance), increased RV energy expenditure, and abnormal distal vascular reflections with exercise, indicating segmental pulmonary vascular remodeling. Four-dimensional flow MRI revealed disturbed flow patterns and trends toward increased viscous energy loss across the left heart and pulmonary circulation. Global gene differences were minimal, likely reflecting the limited statistical power for detecting individual differentially expressed genes in this modest cohort; however, pathway analysis revealed upregulation of RNA metabolism and downregulation of mitochondrial pathways in the RV dysfunction subgroup. Long-read sequencing further identified selective isoform expression in key cardiac genes, highlighting differential regulation in PH-HFpEF with RV dysfunction.
conclusionsThis integrative methodological framework of vessel-specific wave mechanics and myocardial transcriptomics advances the mechanistic understanding of left heart-pulmonary vascular remodeling in PH-HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.